Anna Tran

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker, Nicholas D. James, Chris Brawley et al. · The Lancet · 2018 · 1.3K citations · Full text

Medicine, Oncology, Urology +13

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)

Chris Parker, Adrian Cook, Noel W. Clarke et al. · Annals of Oncology · 2024 · 49 citations · Full text

Medicine, Radiation Oncology, Surgery +17

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15